Caribou Biosciences, Inc. Capital Expenditures
Caribou Biosciences, Inc. (CRBU) reported Capital Expenditures of $73.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13
- Caribou Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $1.00K, a 99.76% decline year-over-year.
- Caribou Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $72.00K, a 93.09% decline year-over-year.
- Caribou Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was -$216.00K, a 141.70% decline year-over-year.
- Caribou Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $115.00K, a 82.91% decline year-over-year.
- Caribou Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $1.36M, a 72.15% decline from fiscal 2024.
- Caribou Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $4.88M, a 57.98% decline from fiscal 2023.
- Caribou Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $11.61M, a 79.93% increase from fiscal 2022.
- Caribou Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $6.45M, a 204.29% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $73.00K 10-Q · filed 2026-08-13 | -$143.00K derived: sum of 3 quarters · filed 2026-08-13 | -$28.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $72.00K 10-Q · filed 2026-05-07 | -$144.00K derived: sum of 2 quarters · filed 2026-05-07 | -$29.00K derived: sum of 3 quarters · filed 2026-05-07 | $389.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$216.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$101.00K derived: sum of 2 quarters · filed 2026-03-05 | $317.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.36M 10-K · filed 2026-03-05 |
| 2025-09-30 | $115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $533.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.57M 10-Q · filed 2025-11-12 | $2.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $418.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.46M 10-Q · filed 2026-08-13 | $1.98M derived: sum of 3 quarters · filed 2026-08-13 | $2.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.04M 10-Q · filed 2026-05-07 | $1.56M derived: sum of 2 quarters · filed 2026-05-07 | $2.23M derived: sum of 3 quarters · filed 2026-05-07 | $4.47M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $518.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.19M derived: sum of 2 quarters · filed 2026-03-05 | $3.43M derived: sum of 3 quarters · filed 2026-03-05 | $4.88M 10-K · filed 2026-03-05 |
| 2024-09-30 | $673.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.91M derived: sum of 2 quarters · filed 2025-11-12 | $4.36M 10-Q · filed 2025-11-12 | $6.64M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.69M 10-Q · filed 2025-08-12 | $5.97M derived: sum of 3 quarters · filed 2025-08-12 | $10.72M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.45M 10-Q · filed 2025-05-08 | $3.73M derived: sum of 2 quarters · filed 2025-05-08 | $8.48M derived: sum of 3 quarters · filed 2025-05-08 | $11.03M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $7.03M derived: sum of 2 quarters · filed 2025-03-10 | $9.58M derived: sum of 3 quarters · filed 2025-03-10 | $11.61M 10-K · filed 2025-03-10 |
| 2023-09-30 | $4.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $7.30M derived: sum of 2 quarters · filed 2024-11-06 | $9.34M 10-Q · filed 2024-11-06 | $11.09M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $2.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.58M 10-Q · filed 2024-08-06 | $6.34M derived: sum of 3 quarters · filed 2024-08-06 | $7.70M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $2.03M 10-Q · filed 2024-05-07 | $3.79M derived: sum of 2 quarters · filed 2024-05-07 | $5.14M derived: sum of 3 quarters · filed 2024-05-07 | $7.76M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $3.11M derived: sum of 2 quarters · filed 2024-03-11 | $5.73M derived: sum of 3 quarters · filed 2024-03-11 | $6.45M 10-K · filed 2024-03-11 |
| 2022-09-30 | $1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.97M derived: sum of 2 quarters · filed 2023-11-07 | $4.70M 10-Q · filed 2023-11-07 | $5.38M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.34M 10-Q · filed 2023-08-08 | $4.03M derived: sum of 3 quarters · filed 2023-08-08 | $4.96M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $723.00K 10-Q · filed 2023-05-09 | $1.41M derived: sum of 2 quarters · filed 2023-05-09 | $2.34M derived: sum of 3 quarters · filed 2023-05-09 | $2.82M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $685.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.61M derived: sum of 2 quarters · filed 2023-03-09 | $2.10M derived: sum of 3 quarters · filed 2023-03-09 | $2.12M 10-K · filed 2023-03-09 |
| 2021-09-30 | $930.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.41M derived: sum of 2 quarters · filed 2022-11-08 | $1.44M 10-Q · filed 2022-11-08 | $1.46M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $484.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $506.00K 10-Q · filed 2022-08-09 | $533.00K derived: sum of 3 quarters · filed 2022-08-09 | $547.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $22.00K 10-Q · filed 2022-05-09 | $49.00K derived: sum of 2 quarters · filed 2022-05-09 | $63.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $41.00K derived: sum of 2 quarters · filed 2022-03-21 | $317.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $290.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $276.00K 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $884.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |